AGTC Selected as Top Company in the University of Florida’s 2017 Gator100
February 10 2017 - 4:01PM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that the company has been
selected as the top company in the 2017 Gator100 awards.
The Gator100, named after the University of
Florida's mascot, recognizes and celebrates the 100 fastest-growing
businesses in the world that are either owned or led by University
of Florida graduates. The annual award is sponsored by the
University's Entrepreneurship & Innovation Center and
Warrington College of Business. The winning companies were
announced earlier today at the Gator100 Awards Gala at the
University of Florida.
“We are grateful to the University of Florida
for its ongoing support as we have evolved from a small startup to
a publicly traded company actively enrolling patients in two
critical trials to evaluate gene therapies for rare ocular
conditions,” said Sue Washer, President and CEO of AGTC. “We are
proud to be recognized alongside so many accomplished and diverse
peers who are making a positive impact across a diverse group of
leading industries.”
AGTC was originally located within the
University of Florida's Sid Martin Biotechnology Incubator and the
company maintains extensive ties to the University through multiple
Sponsored Research Agreements, covering basic research projects and
supporting pre-clinical and clinical development for new product
candidates.
“We congratulate AGTC for earning the top spot
in the 2017 Gator100,” said Jamie Kraft, Director of the
Entrepreneurship & Innovation Center at the Warrington College
of Business. “The company’s continued growth reflects its
leadership in the development of innovative gene-based therapies
that have the potential to dramatically improve lives. We are proud
to continue to partner with a company that is making an impact on
patients and the biotechnology industry.”
About
AGTC
AGTC is a clinical-stage biotechnology company
that uses its proprietary gene therapy platform to develop products
designed to transform the lives of patients with severe diseases,
with an initial focus in ophthalmology. AGTC's lead product
candidates are designed to treat inherited orphan diseases of the
eye, caused by mutations in single genes that significantly affect
visual function and currently lack effective medical
treatments.
AGTC's product pipeline includes ophthalmology
programs in X-linked retinoschisis (XLRS), X-linked retinitis
pigmentosa (XLRP), achromatopsia, wet age-related macular
degeneration, and our optogenetics program with Bionic Sight.
AGTC's non-ophthalmology programs include its adrenoleukodystrophy
program and its otology program, which is in pre-clinical
development and the company expects to advance several otology
product candidates into clinical development in the next few years.
Each of AGTC's XLRS, XLRP and adrenoleukodystrophy programs
are partnered with Biogen. AGTC employs a highly-targeted
approach to selecting and designing its product candidates,
choosing to develop therapies for indications having high unmet
medical need that it believes are clinically feasible and present
commercial opportunities. AGTC has a significant intellectual
property portfolio and extensive expertise in the design of gene
therapy products including capsids, promoters and expression
cassettes, as well as, expertise in the formulation, manufacture
and physical delivery of gene therapy products.
IR/PR CONTACTS:
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com
CORPORATE CONTACTS:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024